Companies
Korro Bio
the OPERA (Oligonucleotide Promoted Editing of RNA) platform underpins KRRO-110 (in the REWRITE Phase 1/2a study, with FDA orphan-drug designation granted in March 2025) and the newly selected development candidate KRRO-111,…
- Country
- United States
- Ticker
- NASDAQ:KRRO
AATD editor (KRRO-110/111)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $85 million private placement (PIPE) financing announced March 9, 2026 | nasdaq.com |
| Regulatory approval | Orphan Drug Designation for KRRO-110 from the FDA (March 2025) and the EMA (July 2025) | ir.korrobio.com · synapse.patsnap.com · sec.gov |
| Regulatory approval | FDA Fast Track designation for KRRO-110 | ir.korrobio.com |
| Regulatory approval | FDA Investigational New Drug clearance for RNA editing technology | ir.korrobio.com |
| Revenue | $5.1 million collaboration revenue for the nine months ended September 30, 2025 | ir.korrobio.com |
| Production site | Headquarters includes 50,453 square feet of office and laboratory space at 60 First Street, Cambridge, Massachusetts | archinect.com · ir.korrobio.com |
Independent sources: archinect.com · nasdaq.com · sec.gov · synapse.patsnap.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| RNA editing (ADAR) therapeutics | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.